Rivastigmine Patch
Product Images NDC 0378-9071

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Rivastigmine (NDC 0378-9071). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Instructions For Use Figure A (Image 01)

An illustration diagram showing the components of a Rivastigmine Transdermal System from Mylan Pharmaceuticals Inc. It depicts the pouch packaging, the transdermal patch labeled with the proprietary name, protective liners surrounding the adhesive layer that contains the medicine, and the outside backing of the patch.*

FDA Label Image

Instructions For Use Figure B (Image 02)

Illustration showing recommended application sites for the Rivastigmine transdermal patch. It depicts six body areas: left or right upper arm, left or right side of chest, left or right upper back, and left or right lower back, with dashed rectangles indicating patch placement sites.*

FDA Label Image

Instructions For Use Figure C (Image 03)

Illustration showing a hand holding a packaged Rivastigmine transdermal system patch by Mylan Pharmaceuticals Inc. The package is labeled for transdermal use and indicates it contains one system. The illustration depicts the patch as a square enclosed in protective packaging.*

FDA Label Image

Instructions For Use Figure D (Image 04)

An instructional line drawing showing hands peeling protective liners from a Rivastigmine transdermal patch to expose the sticky surface of the patch's transdermal system.*

FDA Label Image

Instructions For Use Figure E (Image 05)

An instructional illustration showing a person applying a rivastigmine transdermal patch to the upper back. The hands are peeling the patch backing, preparing to place the patch on the skin.*

FDA Label Image

Rivastigmine Structural Formula (Image 06)

Chemical structure of rivastigmine, showing the molecular arrangement including a carbamate group, aromatic ring, and methylated amine.*

FDA Label Image

Figure 1: Cross Section Of The Rivastigmine Transdermal System (Image 07)

A cross-sectional diagram illustrating the layers of a Rivastigmine transdermal patch. It shows the backing film, drug product acrylic matrix, adhesive silicone skin contact layer, and slit protective release liner with raised dimples that are removed before use.*

FDA Label Image

Rivastigmine Transdermal System 4.6 mg/24 Hours Carton Label (Image 08)

Packaging carton for Rivastigmine Transdermal System patch, 4.6 mg/24 hours strength. The label shows the product name, dosage, and usage instructions emphasizing transdermal application. It contains 30 systems and is manufactured by Mylan Pharmaceuticals Inc. Instructions for discarding used patches are included. The NDC code 0378-9070-93 is visible.*

FDA Label Image

Rivastigmine Transdermal System 9.5 mg/24 Hours Carton Label (Image 09)

Packaging label for Rivastigmine Transdermal System 9.5 mg/24 hours patch by Mylan Pharmaceuticals Inc. The label indicates the product contains 30 systems, each delivering 9.5 mg of rivastigmine per 24 hours for transdermal use only. Instructions are provided for discarding the used patch safely, and contact information for Mylan is included.*

FDA Label Image

Rivastigmine Transdermal System 13.3 mg/24 Hours Carton Label (Image 10)

Packaging label for Rivastigmine Transdermal System patch, strength 13.3 mg/24 hours, manufactured by Mylan Pharmaceuticals Inc. The label states each system delivers 13.3 mg over 24 hours and contains 30 systems per package. Instructions for discarding used patches and safety warnings are included. The label includes the NDC 0378-9072-93 and emphasizes transdermal use only.*

FDA Label Image

Figure 2: Rivastigmine Plasma Concentrations Following Dermal 24-hour Transdermal System Application (Image 11)

A line graph showing rivastigmine plasma concentration (ng/mL) over 24 hours after transdermal patch application at three strengths: 13.3 mg/24h, 9.5 mg/24h, and 4.6 mg/24h. The graph includes mean values with variability bars and shows concentration changes over time for each dose.*

FDA Label Image

Figure 3: Time Course Of The Change From Baseline In Adas-cog Score For Patients Observed At Each Time Point In Study 1 (Image 12)

Line graph showing least square means plus/minus SEM change from baseline ADAS-Cog rating over 24 weeks of treatment. The graph compares four groups: 17.4 mg/24 hours patch, 9.5 mg/24 hours patch, 6 mg capsules BID, and placebo. Positive changes indicate clinical improvement, and negative changes indicate clinical decline over time.*

FDA Label Image

Figure 4: Distribution Of Adcs-cgic Scores For Patients Completing Study 1 (Image 13)

A bar chart comparing patient percentages across ADCS-CGIC rating categories for four treatments: rivastigmine 17.4 mg/24 hours patch, rivastigmine 9.5 mg/24 hours patch, capsules 6 mg BID, and placebo. The ratings range from markedly improved to markedly worse, showing distribution of patient outcomes by treatment group.*

FDA Label Image

Figure 5: Time Course Of The Change From Double-blind Baseline In Adcs-iadl Score For Patients Observed At Each Time Point In Study 2 (Image 14)

A line graph showing ADCS-iADL change from baseline (LS means SEM) over weeks of treatment for Rivastigmine Transdermal System patches at doses of 13.3 mg/24hr and 9.5 mg/24hr. The graph illustrates clinical improvement versus clinical decline, with data points up to 48 weeks.*

FDA Label Image

Figure 6: Time Course Of The Change From Double-blind Baseline In Adas-cog Score For Patients Observed At Each Time Point In Study 2 (Image 15)

A line graph comparing clinical improvement measured by ADAS-Cog change from baseline (LS means and SEM) over 52 weeks of treatment between two rivastigmine transdermal systems, 13.3 mg/24hr and 9.5 mg/24hr. The vertical axis indicates clinical improvement or decline, and the horizontal axis shows weeks of treatment. The 13.3 mg/24hr dose shows greater improvement over time compared to the 9.5 mg/24hr dose.*

FDA Label Image

Figure 7: Time Course Of The Change From Baseline In Sib Score For Patients Observed At Each Time Point (modified Full Analysis Set–locf) (Image 16)

A line graph depicting the least squares mean change with standard errors over 24 weeks of treatment comparing two rivastigmine transdermal patch sizes (15 cm² and 5 cm²). The vertical axis shows LS mean change, with clinical improvement above zero and clinical decline below. Data points at 0, 8, 16, and 24 weeks illustrate statistical significance at weeks 16 and 24 for the 15 cm² patch relative to the 5 cm² patch.*

FDA Label Image

Figure 8: Time Course Of The Change From Baseline In Adcs-adl-siv Score For Patients Observed At Each Time Point (modified Full Analysis Set–locf) (Image 17)

A line chart comparing the least squares mean change in STE over 24 weeks of treatment between two doses of rivastigmine transdermal system: 15 cm² (solid line) and 5 cm² (dashed line). The vertical axis shows LS mean change with error bars, indicating clinical improvement or decline, while the horizontal axis represents treatment duration in weeks. Statistical values and confidence intervals for differences are shown at each time point.*

FDA Label Image

Instructions For Use Figure F (Image 18)

Illustration showing the application of a transdermal patch on the upper back between the shoulder blades. The image depicts a person from behind applying the patch, relevant to the rivastigmine transdermal patch dosage form.*

FDA Label Image

Instructions For Use Figure G (Image 19)

An instructional illustration showing a person applying a transdermal patch to the upper back. One hand is holding the patch while the other hand is pressing it onto the skin with a circular motion, indicating proper application technique.*

FDA Label Image

Instructions For Use Figure H (Image 20)

An instructional diagram illustrating disposal steps for Rivastigmine transdermal patches. It shows folding the sticky sides of the patch together, sliding the folded patch into an empty pouch, and placing it in a trash container to keep away from children and pets. The diagram includes a visible label showing the product name 'Rivastigmine transdermal system' and the Mylan logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.